Acute Ischemic Injury Program
Preservation of function following acute ischemic injury (e.g., stroke)
Pre-clinicalActive
Key Facts
Indication
Preservation of function following acute ischemic injury (e.g., stroke)
Phase
Pre-clinical
Status
Active
Company
About Egret Therapeutics
Egret Therapeutics is an early-stage biotech leveraging small molecule modulation of innate immunity to treat acute neurological injuries and disorders. Founded in 2021, the company is in a pre-clinical or very early clinical stage, targeting the significant unmet need in stroke recovery and related cognitive deficits. As a private, pre-revenue entity, its success hinges on validating its novel mechanism, advancing a lead candidate into clinical trials, and securing further investment. The company operates in the competitive but high-potential neuroimmunology space.
View full company profile